A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

121 sites for NCT04660344

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Infiltrating Bladder Urothelial Carcinoma

atezolizumab

immunotherapy

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

116 sites for NCT04740918

ERBB2 Amplification, +7 more biomarkers

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

207 sites for NCT04513925

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Non-Small Cell Lung Carcinoma

atezolizumab, +1 more drug

immunotherapy

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

161 sites for NCT04746924

PD-L1 High Expression (TPS >= 50%)

Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition

ociperlimab, +1 more drug

immunotherapy

A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

51 sites for NCT04665843

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Head and Neck Squamous Cell Carcinoma

atezolizumab, +1 more drug

immunotherapy

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

67 sites for NCT04262856

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition

domvanalimab, +2 more drugs

immunotherapy

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

45 sites for NCT04463771

Deficient DNA Mismatch Repair (dMMR), +23 more biomarkers

Endometrial Carcinoma, +2 more conditions

epacadostat, +2 more drugs

immunotherapy, +1 more type

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

30 sites for NCT03337698

PD-L1 High Expression (TPS >= 50%)

Non-Small Cell Lung Carcinoma

atezolizumab, +14 more drugs

chemotherapy, +4 more types

CRAFT: The NCT-PMO-1602 Phase II Trial

4 sites for NCT04551521

AKT1 Amplification, +78 more biomarkers

Malignant Solid Tumor

alectinib, +6 more drugs

immunotherapy, +1 more type

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

7 sites for NCT04931654

PD-L1 High Expression (TPS >= 1%), +2 more biomarkers

Non-Small Cell Lung Carcinoma, +1 more condition

AZD7789

immunotherapy

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

1 site for NCT04849364

AKT1 Amplification, +141 more biomarkers

Invasive Breast Carcinoma

atezolizumab, +3 more drugs

chemotherapy, +2 more types

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

23 sites for NCT04291105

PD-L1 High Expression (TPS >= 50%)

Cutaneous Melanoma, +3 more conditions

cemiplimab, +2 more drugs

immunotherapy